Opinion|Videos|January 23, 2025
Endocrine Sensitivity and the Prognostic and Clinical Implications
Author(s)Katherine Clifton, MD, Shipra Gandhi, MD
Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What proportion of patients with HR+/HER2– breast cancer experience resistance to first-line endocrine therapy plus CDK4/6 inhibitor?
- What are some of the mechanisms of resistance that can emerge following endocrine therapy and CDK4/6 inhibitors in HR+/HER2– breast cancer?
- How you think about endocrine resistance in the post-CDK4/6 setting? What signals—clinical, molecular, or otherwise—influence your treatment sequencing decisions?
- How does treatment resistance after first-line treatment create challenges in selecting second-line therapies?
Advertisement
Related to this article
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.
Advertisement
Advertisement
Trending on OncLive
1
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
2
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
3
Dive Into Key Data and Presentations From EHA 2026
4
Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML
5